UBS Group’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

UBS Group’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-429	Closed	-$6K	–	8281
2016 Q2	$6K	Sell	429 -181	-30%	-$2.33K	﹤0.01%	7090
2016 Q1	$8K	Sell	610 -1,472	-71%	-$20.6K	﹤0.01%	6820
2015 Q4	$33K	Sell	2,082 -702	-25%	-$11.1K	﹤0.01%	6248
2015 Q3	$42K	Buy	2,784 +129	+5%	+$2.79K	﹤0.01%	5996
2015 Q2	$64K	Buy	2,655 +2,255	+564%	+$54K	﹤0.01%	5793
2015 Q1	$9K	Sell	400 -113	-22%	-$2.99K	﹤0.01%	7770
2014 Q4	$13K	Buy	+513	New	+$15K	﹤0.01%	8184

UBS Group's SGNT Position: Q3 2016 in Review

UBS Group sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 429 shares — an estimated $6K sold.

UBS Group first reported a position in SGNT in Q4 2014 and held it in 7 quarters. The position peaked at $64K in Q2 2015. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.

UBS Group reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
UBS Group sold 429 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $6K.
UBS Group first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q4 2014 and held it in 7 quarters.
UBS Group's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $64K in Q2 2015.
0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.

Based on UBS Group's 13F filing for Q3 2016, filed 14 Nov 2016.